Sonia Capellero

List of Publications by Year
in descending order

11 papers	177 citations	1163117 8 h-index	1372567 10 g-index
11 all docs	11 docs citations	11 times ranked	336 citing authors

#	Article	IF	Citations
1	HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Research and Treatment, 2011, 130, 29-40.	2.5	47
2	Adoptive immunotherapy against ovarian cancer. Journal of Ovarian Research, 2016, 9, 30.	3.0	33
3	CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. Clinical Cancer Research, 2020, 26, 6321-6334.	7.0	24
4	Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34+ cells and T lymphocytes: Implications for the use of low viral doses and large-size vectors. Journal of Biotechnology, 2011, 156, 218-226.	3.8	14
5	Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells. International Journal of Molecular Sciences, 2022, 23, 833.	4.1	14
6	Efficient Transcriptional Targeting of Human Hematopoietic Stem Cells and Blood Cell Lineages by Lentiviral Vectors Containing the Regulatory Element of the Wiskott-Aldrich Syndrome Gene. Stem Cells, 2009, 27, 2815-2823.	3.2	11
7	Adoptive immunotherapy against sarcomas. Expert Opinion on Biological Therapy, 2015, 15, 517-528.	3.1	11
8	Sustained Long-Term Engraftment and Transgene Expression of Peripheral Blood CD34+Cells Transduced with Third-Generation Lentiviral Vectors. Stem Cells, 2008, 26, 1620-1627.	3.2	8
9	Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer. Scientific Reports, 2020, 10, 6478.	3.3	8
10	PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. Cells, 2020, 9, 442.	4.1	7
11	Abstract 3102: Identification of actionable cancer genes and treatment options for metastatic ovarian carcinomas using patient-derived xenografts and PDX-derived tumor cells. , 2018, , .		0